HBM (HKG:2142) said it has expanded its collaboration with AstraZeneca to broaden joint discovery and development of next-generation biotherapeutics, including antibody-drug conjugates and T-cell engagers, according to a Monday Hong Kong bourse filing.

The amendment to their March collaboration, option, and licence agreement keeps the original financial framework unchanged, the company said.